Tag: medical education

  • Psych Meds Are Not the Enemy. Bad Medicine Is

    Psych Meds Are Not the Enemy. Bad Medicine Is

    There is a dangerous difference between criticizing bad psychiatric practice and stigmatizing psychiatric illness.

    I have criticized aspects of psychiatry many times. I believe our field should be open to critique. We should question our prescribing habits. We should challenge lazy diagnosis. We should acknowledge when medications are used too quickly, continued too long, or substituted for the deeper work of psychotherapy, lifestyle change, social support, and careful clinical formulation.

    Psychiatry should never be above criticism.

    But criticism of psychiatric practice is not the same thing as denying the legitimacy of psychiatric illness.

    And right now, that line is being blurred.

    Serious Mental Illness Is Real

    One thing you will never hear me say is that psychiatric disease is not real.

    Schizophrenia is real.
    Bipolar disorder is real.
    Severe major depression is real.
    Catatonia is real.
    Psychotic depression is real.
    Obsessive-compulsive disorder can be profoundly disabling.
    Posttraumatic stress disorder can devastate a person’s life.

    These are not character flaws. They are not weakness. They are not simply failures of lifestyle, discipline, resilience, spirituality, or mindset.

    They are legitimate medical illnesses.

    That does not mean every painful experience is a disease. It does not mean every person who is grieving, anxious, overwhelmed, lonely, or struggling needs a diagnosis or a medication. In fact, one of the most important tasks in psychiatry is knowing the difference.

    Some people need medication.

    Some people need psychotherapy.

    Some people need sleep, exercise, nutrition, structure, social connection, housing, safety, meaning, accountability, or community.

    Many people need several of these at the same time.

    The goal is not to medicalize all suffering. The goal is to recognize real illness when it is present and treat it with the seriousness it deserves.

    The Problem Is Not “Medication”

    Psychiatric medications are often discussed as if they are inherently suspicious.

    But medication is not the enemy.

    Bad medicine is.

    A medication can be life-changing when used for the right condition, in the right person, at the right time, for the right reason.

    The same medication can be harmful when used carelessly, without a clear diagnosis, without follow-up, without discussion of risks and benefits, or without a plan for reassessment.

    That is not unique to psychiatry.

    Antibiotics can be lifesaving, but inappropriate antibiotic use causes harm. Opioids can be appropriate in some clinical contexts, but reckless prescribing devastated communities. Steroids can be powerful tools, but long-term unnecessary use can create major problems.

    The issue is not whether medications are “good” or “bad.”

    The issue is whether we are practicing medicine well.

    Deprescribing Matters, But It Is Not a Mental Health Policy

    Deprescribing is important.

    Every psychiatrist I know has experience reducing, simplifying, or stopping medications when the risks outweigh the benefits or when the original indication no longer makes sense.

    This is not a fringe idea. It is part of daily psychiatric practice.

    We stop medications that are not helping.
    We reduce unnecessary polypharmacy.
    We simplify regimens when possible.
    We monitor side effects.
    We reassess diagnoses.
    We talk with patients about what still makes sense.

    Good psychiatry includes deprescribing.

    But deprescribing alone will not solve the mental health crisis.

    People cannot deprescribe their way out of a lack of psychiatric beds. They cannot deprescribe their way out of months-long waitlists. They cannot deprescribe their way out of poverty, homelessness, trauma, addiction, loneliness, or a collapsing continuum of care.

    And they cannot deprescribe their way out of schizophrenia, mania, catatonia, psychotic depression, or severe melancholic depression.

    When we frame the mental health crisis primarily as a problem of overprescribing, we oversimplify a system failure.

    We ignore the shortage of psychiatrists. We ignore the lack of access to psychotherapy. We ignore inadequate visit times, fragmented care, insurance barriers, emergency departments boarding psychiatric patients for days, and the near disappearance of a true continuum of care.

    Those are not solved by telling people to take fewer medications.

    The Risk of Stigma Dressed Up as Reform

    My concern is not that we are talking about prescribing quality. We should be talking about that.

    My concern is that the rhetoric around psychiatric medications often sends a dangerous message to people who already feel ashamed.

    Many patients with serious mental illness already struggle with the idea of needing medication.

    They worry it means they are weak.
    They worry it means they are broken.
    They worry it means they are dependent.
    They worry it means they are not trying hard enough.
    They worry others will see them differently.

    When public conversations frame psychiatric medications as the central villain, those patients hear something very different from “we need better prescribing.”

    They hear:

    You are dependent.
    You are addicted.
    You are taking the easy way out.
    You should be able to fix this naturally.
    You are the problem.

    That is not empowerment.

    That is stigma.

    And for some patients, that stigma can be dangerous. It can lead people to stop medications abruptly, avoid treatment, disengage from care, relapse, or delay help until a crisis occurs.

    Of course patients should be informed. Of course they should understand risks and benefits. Of course they should have a voice in treatment decisions.

    But informed consent should not become fear-based messaging. And reform should not become another way of shaming people with serious psychiatric illness.

    Better Medicine Means Holding Two Truths

    The future of psychiatry depends on our ability to hold two truths at the same time.

    First, psychiatric illness is real and can be devastating.

    Second, psychiatry must be careful not to overdiagnose, overprescribe, or turn normal human suffering into lifelong pathology.

    Both truths matter.

    If we only emphasize the first, we risk medicalizing everything.

    If we only emphasize the second, we risk abandoning people with serious illness.

    Real psychiatric care lives in the tension between those truths.

    It requires humility. It requires careful diagnosis. It requires honest conversations about uncertainty. It requires medication when appropriate, psychotherapy when appropriate, lifestyle intervention when appropriate, social support when appropriate, neuromodulation when appropriate, and deprescribing when appropriate.

    It also requires us to say clearly that some people need medication, and that needing medication is not a moral failure.

    The Goal Is Better Medicine

    The goal is not to prescribe more.

    The goal is not to prescribe less.

    The goal is to prescribe better.

    Better diagnosis.
    Better informed consent.
    Better follow-up.
    Better access to psychotherapy.
    Better use of lifestyle interventions.
    Better systems of care.
    Better deprescribing when medications are no longer needed.
    Better protection for people whose medications are the reason they are alive, stable, working, parenting, studying, and functioning.

    We do not fix psychiatry by pretending psychiatric medications are always the answer.

    But we also do not fix psychiatry by pretending they are the enemy.

    Psych meds are not the enemy.

    Bad medicine is.

  • We say we care about mental health in America

    We say we care about mental health in America

    We say we care about mental health in America.
    But the data—and my front-line experience—say otherwise.

    We are overmedicating, underfunding, and pathologizing poverty, trauma, and stress.
    Instead of addressing why people are sick, we throw pills at symptoms.

    đź§  In my latest article for Psychiatric Times, I make the case that we’ve built a system that profits off disease—not health.
    We’re not solving the problem. We’re institutionalizing it.

    If we want to make America healthy again, we need to stop doing the wrong things.

    👉 Read the full piece here: https://www.psychiatrictimes.com/view/if-we-want-to-make-america-healthy-again-we-are-doing-the-wrong-thing

  • Is Antidepressant Withdrawal Overhyped? What the Evidence Really Says

    Is Antidepressant Withdrawal Overhyped? What the Evidence Really Says

    In my clinical practice, I’ve often found myself scratching my head over the narrative surrounding antidepressant withdrawal.

    I’m not denying that withdrawal is real—it is. And for a small subset of patients, it can be quite distressing. But what I am saying is this: it’s not nearly as common, dramatic, or dangerous as some online circles and sensational stories would have you believe.

    I’ve seen countless patients abruptly stop antidepressants and experience no withdrawal symptoms. I’ve also aggressively tapered antidepressants in patients with bipolar disorder to prevent mood destabilization—again, with little to no evidence of withdrawal. This isn’t a one-off observation. It’s a consistent clinical pattern I’ve noted for years. So, I asked myself: What does the data actually say?

    The Evidence

    A 2024 meta-analysis published in JAMA Psychiatry examined 49 randomized controlled trials and finally gave us some clarity.

    The results?
    âś… People discontinuing antidepressants reported on average just one more symptom than those who either continued medication or discontinued a placebo.
    âś… The most commonly reported symptoms in the first two weeks were dizziness, nausea, vertigo, and nervousness—exactly what I’ve seen clinically.
    âś… Critically, the average number of symptoms fell below the threshold for what’s considered a clinically significant discontinuation syndrome.
    âś… There was no link between discontinuation and worsening depression, suggesting that if mood symptoms return, it’s likely a relapse—not withdrawal.

    Why This Matters

    There are vocal groups online—often with clear anti-psychiatry agendas—who focus exclusively on rare, severe cases of withdrawal and present them as the norm. The goal is simple: to scare people away from psychiatry and evidence-based treatment using emotional testimonials instead of clinical reality.

    Let’s be honest—those cases do exist, but they are not representative of what most patients experience.

    As clinicians, we should remain cautious and responsible. Yes, we should taper medications thoughtfully. Yes, we should prepare patients for the possibility of withdrawal symptoms. But we also shouldn’t scare them into avoiding treatment—or make them feel trapped on medications for life.

    Bottom Line

    Antidepressant withdrawal can happen. It can be uncomfortable. But it’s rarely severe and almost never dangerous. The fear around it has been overstated by those with an ax to grind. We owe it to our patients to treat based on evidence, not anecdotes.

  • Brexpiprazole + Sertraline: A New Hope for PTSD Treatment

    Brexpiprazole + Sertraline: A New Hope for PTSD Treatment

    We’ve all seen it: PTSD that won’t budge. Patients try sertraline or paroxetine—the so-called “gold standards”—and walk away with little more than side effects and a sense of failure.

    Enter a new contender: brexpiprazole + sertraline.

    A recent Phase 3 randomized controlled trial might finally offer something real for those stuck in the PTSD trenches.

    🚨 The Results

    In a study across 86 sites with over 550 adults, adding brexpiprazole (2–3 mg) to sertraline (150 mg) led to a 5.6-point greater reduction on the CAPS‑5 (the gold-standard PTSD measure) compared to sertraline + placebo. That’s not a marginal win—it’s a clinically significant shift, especially in a treatment-resistant population.

    Responder rates tell the story even clearer:

    • 68.5% of patients on the combo had ≥30% reduction in symptoms
    • Compared to 48.2% on sertraline alone
    • That’s a +20% absolute response rate boost

    And the improvements weren’t just short-lived. Benefits held through 12 weeks, even during a post-treatment observation period. No relapse, no rebound—just stability.

    đź§© More Than Symptom Checklists

    It wasn’t just about PTSD symptoms. This combo also:

    • Improved psychosocial functioning (B-IPF scores)
    • Reduced anxiety and depression (HADS)
    • Lowered global illness severity (CGI-S)
    • Helped with all symptom clusters, including reexperiencing, avoidance, and hyperarousal

    That’s rare. Most meds in psychiatry hit one or two domains and leave the rest hanging. This one made a dent where it counts: function, resilience, and real-world relief.

    ⚠️ What About Side Effects?

    Brexpiprazole is still an atypical antipsychotic, so there’s baggage. But the trial data suggest it’s relatively well-tolerated:

    • Fatigue: 6.8%
    • Weight gain: 5.9%
    • Somnolence: 5.4%
    • Discontinuation due to AEs? Just 3.9%, vs 10.2% in placebo.

    No new safety signals. No psychosis worsening. Not perfect, but not the metabolic disaster zone we see with other agents.

    🚀 What’s Next?

    The FDA is reviewing this combo

    For those of us treating chronic PTSD, this may be a real tool—not just a shiny new molecule with good marketing.

    Until then, it’s worth paying attention. Because when sertraline alone doesn’t cut it—and we know it often doesn’t—this combo could offer a lifeline.

  • Understanding Psychiatry: Science vs. Skepticism

    Understanding Psychiatry: Science vs. Skepticism

    đź§  â€śPsychiatry is a scam.” “Big Pharma controls your brain.” “Mental illness isn’t real.”

    You’ve heard the takes. Now here’s the truth.

    In my new article for Psychiatric Times, I dive headfirst into the controversy:
    👉 Understanding Psychiatry: Navigating Skepticism and Science
    https://www.psychiatrictimes.com/view/understanding-psychiatry-navigating-skepticism-and-science

    I don’t dodge the hard questions—about overmedication, broken trust, and bad science—but I also push back against lazy anti-psychiatry takes that ignore the very real suffering of patients.

    If you care about the future of mental health care, this one’s worth your time.

  • Reject dogma—embrace nuance in Psychiatry

    🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


    🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


    🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

    The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

  • RFK Jr. Claims He’ll Identify the Cause of Autism by September

    RFK Jr. Claims He’ll Identify the Cause of Autism by September

    In a bold statement this week, Robert F. Kennedy Jr. announced that he will reveal the definitive cause of autism by September. Kennedy, a longtime critic of childhood vaccine programs, did not provide specific scientific details or a research plan, but implied that his administration would prioritize transparency and independent investigations into the condition’s origins.

    The claim has sparked immediate controversy. Autism is a complex neurodevelopmental condition with a strong genetic foundation and a wide range of potential environmental influences—none of which have yielded a singular, definitive cause. The scientific consensus, built over decades of rigorous research, continues to support a multifactorial model rather than a simplistic explanation.

    Many highly intelligent and dedicated scientists have spent years studying autism without identifying a single, unifying cause. One of the recurring issues that arises when politics intersects with science is a resistance to the idea that these are nuanced, multifaceted conditions. It’s not the most satisfying explanation—but it is consistent with the best evidence we have. My fear is that this type of investigation, under political pressure, could prematurely identify a false causal agent—such as vaccines—and reignite a harmful narrative that has already been thoroughly debunked.

    Kennedy’s history of promoting vaccine-autism links adds further concern. The CDC, WHO, and a vast body of peer-reviewed research have all concluded there is no credible evidence connecting vaccines to autism. Suggesting otherwise not only undermines public trust in science and medicine—it risks the health of entire communities by fueling vaccine hesitancy.

    For families and individuals affected by autism, the promise of discovering its origins is understandably compelling. But it’s critical that we approach that pursuit with scientific integrity, not political expediency.

  • 🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

    A recent study published in Frontiers in Psychiatry reveals that individuals using antidepressants experienced notable weight gain over a six-year period.​

    Key Findings:

    • Increased Weight Gain:​
      • Participants who used antidepressants showed an average weight increase of approximately 2% of their baseline body weight compared to non-users.​
    • Higher Obesity Risk:​
      • Those without obesity at the study’s start had double the risk of becoming obese if they used antidepressants throughout the six years.​

    Implications:

    With the widespread use of antidepressants and the global obesity epidemic, integrating weight management and metabolic monitoring into depression treatment plans is crucial.​

    link: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464898/full

  • Challenges of Antidepressant Management in Primary Care

    Challenges of Antidepressant Management in Primary Care

    Discussions about the potential overprescribing of antidepressants must begin with an understanding of who is doing most of the prescribing. In the U.S., primary care physicians (PCPs) write the majority of antidepressant prescriptions, with estimates suggesting that 60–80% originate from primary care rather than psychiatry (Mojtabai & Olfson, 2011; Mark et al., 2014). This prescribing pattern reflects broader trends in mental health treatment, where primary care has become the frontline for managing depression and other mood disorders.

    Several factors contribute to this dynamic:

    • Limited access to psychiatrists: Many patients, especially in rural or underserved areas, face long wait times or geographic barriers to seeing a psychiatrist.
    • Overlap with medical conditions: PCPs frequently manage conditions like chronic pain, insomnia, and fatigue, for which antidepressants may be considered as part of the treatment plan.
    • Continuity of care: Patients often have longstanding relationships with their primary care providers, making them more comfortable discussing mood symptoms in this setting.
    • Psychiatric referral limitations: Many psychiatrists focus on complex or treatment-resistant cases, meaning initial treatment often falls under primary care.

    Challenges and Considerations

    While primary care plays a crucial role in mental health treatment, concerns exist regarding the effectiveness of antidepressant management in this setting:

    • Suboptimal dosing and medication selection: Studies suggest that antidepressants prescribed in primary care settings may be dosed too low or not adequately adjusted, potentially leading to partial response or treatment failure (Carrasco & Sandner, 2005). Additionally, there is a higher likelihood of using older antidepressants, which may have a less favorable side effect profile.
    • Lack of therapy integration: Guidelines recommend a combination of medication and psychotherapy for moderate-to-severe depression (APA, 2010), yet PCPs may have limited time, training, or referral resources to ensure therapy is included.
    • Potential misdiagnosis: Depressive symptoms can overlap with other psychiatric and medical conditions, leading to misdiagnosis or inappropriate treatment. For example, bipolar disorder is often misdiagnosed as major depressive disorder in primary care, which can result in inadequate treatment and risk of mood destabilization (Hirschfeld et al., 2003).

    Addressing These Challenges

    Several strategies can improve antidepressant management within primary care settings:

    • Collaborative care models: Studies show that integrating mental health professionals within primary care teams leads to improved outcomes, including higher remission rates and better adherence (Archer et al., 2012).
    • Standardized screening and follow-up: Implementing tools like the PHQ-9 for monitoring depression severity can help guide treatment decisions and ensure timely adjustments.
    • Education and decision support: Providing PCPs with continuing education on psychiatric prescribing and decision-support tools can enhance treatment precision.
    • Improved access to therapy: Expanding tele-therapy options and embedding behavioral health providers in primary care clinics can help bridge the gap between medication and psychotherapy.

    Conclusion

    Given the high volume of antidepressant prescriptions originating from primary care, ensuring optimal management is critical to improving patient outcomes. Strengthening collaboration between PCPs and mental health specialists, enhancing diagnostic accuracy, and integrating therapy referrals can help address current limitations.

    Call to Action: If you are a healthcare professional involved in prescribing antidepressants, what strategies have you found effective in improving patient outcomes? Share your insights and experiences below.

  • What Happens When We Ignore Scientific Evidence?

    What Happens When We Ignore Scientific Evidence?

    When we reject the overwhelming scientific consensus that vaccines do not cause autism, we enter a dangerous world—one where facts are disregarded, misinformation thrives, and preventable diseases make a deadly comeback.

    The Real Consequences of Vaccine Hesitancy

    Vaccine hesitancy isn’t just a debate—it has real, measurable consequences

    Measles Outbreaks: In early 2025, Texas experienced its most severe measles outbreak in nearly 30 years, with 198 confirmed cases as of March 7. The outbreak has resulted in 23 hospitalizations and one measles-related death—the first in the nation in a decade. The outbreak is primarily concentrated in rural Gaines County, where vaccination rates are notably low.

    Whooping Cough Resurgence: Cases of pertussis (whooping cough) have increased in areas with lower vaccination rates, endangering infants who are too young to be fully vaccinated.

    Polio’s Return: In 2022, a case of paralytic polio emerged in New York, decades after the disease had been eliminated in the U.S., traced back to vaccine hesitancy and low immunization coverage.

    Ignoring evidence doesn’t just impact individuals—it threatens public health as a whole

    Addressing Concerns: Why the Autism Myth Persists

    Some parents worry about vaccine safety due to outdated or misleading claims, most notably a fraudulent 1998 study linking vaccines to autism. This study was retracted, and extensive research—including studies on hundreds of thousands of children—has confirmed no link between vaccines and autism. Yet, fear and misinformation persist, fueled by social media echo chambers and distrust in institutions.

    While vaccine side effects do exist, they are typically mild (e.g., temporary soreness, fever) and far outweighed by the risks of the diseases they prevent. Scientific inquiry should always continue, but dismissing decades of rigorous research in favor of debunked myths endangers lives.

    What Can We Do?

    Combatting vaccine misinformation requires action. Here’s how you can help

    âś” Speak Up: Correct misinformation when you see it, whether online or in conversations with friends and family.

    âś” Rely on Experts: Trust reputable sources like the CDC, WHO, and medical professionals rather than social media influencers or unverified websites.

    âś” Advocate for Science Education: Supporting critical thinking and scientific literacy helps build a society that values evidence over fear.

    âś” Get Vaccinated: Lead by example—being up to date on vaccines protects you and those around you, especially vulnerable populations.

    Science Is Not an Opinion

    Truth is not subjective. If we abandon scientific evidence in favor of belief alone, we risk more than just vaccine-preventable diseases—we risk an era where facts no longer matter. The stakes are too high to let misinformation win.